Atrogi
Sweden - SolnaBiotechnology
Focus: Atrogi is a Swedish biotechnology company focused on small molecule therapeutics for type 2 diabetes and metabolic diseases. The company operates as a pre-revenue biotech with an early-stage pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Atrogi
AI assessmentNot HiringNo open roles listed right now. Follow Atrogi to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ATR-258
Type 2 Diabetes MellitusClinical Trials (3)
NCT07421024Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle
Phase 2Help build intelligence for Atrogi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.